Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:China
third-line treatment of NSCLC |
| gptkbp:ATCCode |
L01EX18
|
| gptkbp:CASNumber |
1058156-90-6
|
| gptkbp:developedBy |
gptkb:Chia_Tai_Tianqing_Pharmaceutical_Group
|
| gptkbp:hasMolecularFormula |
C23H19FN4O3
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits PDGFR
inhibits c-Kit inhibits FGFR inhibits VEGFR |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:hand-foot_syndrome
diarrhea anorexia fatigue hypertension proteinuria hemorrhage |
| gptkbp:synonym |
gptkb:AL3818
|
| gptkbp:target |
gptkb:FGFR1
gptkb:VEGFR2 gptkb:PDGFRα gptkb:VEGFR3 gptkb:c-Kit |
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
gptkb:rhabdomyosarcoma |
| gptkbp:bfsParent |
gptkb:Non-Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Anlotinib
|